|
|
|
|
 |
Scientific Program
from the
Third International Symposium on Resistant
Gram-Positive Infections
( Click on underlined links
below to view actual presentations) |
|
|
|
|
| OCTOBER 9, 2006 |
|
|
|
16:00-18:00 |
|
Gold
Sponsored Symposium |
|
|
Aspects
of Community Antibiotic Failure in CAP caused by S. pneumoniae
Chair
person: E. Rubinstein & J. Schentag
|
| 16:00-16:30 |
|
Macrolide Resistance and Failure in the
Community - N. Daneman (CA)
|
| 16:30-17:00 |
|
Clinical Aspects of CAP Failure in the
Community - S. Deresinski (US)
|
| 17:00-17:30 |
|
Economic Aspects of CAP Failure in the
Community - J.Paladino (US)
|
| 17:30-18:00 |
|
The MOTIV Study - S.Sethi (US)
|
|
|
|
| OCTOBER 10, 2006 |
|
|
|
|
|
|
|
Mechanisms
of Resistance
Chair
persons:
D. Low and C. Rotstein
|
| 8:00:8:30 |
|
Clinical
Impact of Drug Resistant S.pneumoniae Resistance -
T.
File (US)
|
| 8:30-9:00 |
|
Mechanisms
of Resistance in Enterococci - L.
Rice (US) |
| 9:00-9:30 |
|
VanA-type
Methicillin Resistant S. aureus - P. Courvalin (FR) |
| 9:30:10:00 |
|
Resistance
Among S.epidermidis - J. John (US)
|
|
|
|
|
|
Epidemiology
Chair
persons:
J. John and R. Corey
|
| 11:00-11:20 |
|
ATLAS:
Telavancin in cSSSI, A Landmark Trial for MRSA - R. Corey (US) |
| 11:20-11:40 |
|
CA-MRSA
-
USA - S. Fridkin (US) |
| 11:40-12:00 |
|
CA-MRSA
Canadian Aspect - M. Mulvey (CA) |
| 12:00-12:20 |
|
Fluoroquinolone
Resistant S. pneumoniae - D. Low (CA)
|
|
|
|
|
|
|
Virulence Factors
in Gram-positives
Chair
persons:
F. Waldvodel and D.Batts
|
| 13:30-13:50 |
|
Regulation
of Resistance Gene Expression - P.
Courvalin |
| 13:50-14:10 |
|
S.
epidermidis-
Not Such an Innocent Pathogen - M. Otto (US) |
| 14:10-14:30 |
|
S.aureus
- An Evolving Clinical Pathogen - D. Batts (US)
|
| 14:30-14:50 |
|
Foreign
Bodies, Biofilms and Catheter Sepsis - I. Raad (US)
|
|
|
|
| 16:00-18:00 |
|
Platinum
Sponsored Symposium |
|
|
MRSA: Considerations for
Selecting Appropriate Therapies
Chair
Person: G. Ralph Corey
|
| 16:00-16:10 |
|
Welcome
and Introduction - R. Corey (US) |
| 16:10-16:40 |
|
PK/PD of
Anti-gram-positive Agents Against MRSA - K. Rodvold (US) |
| 16:40-17:10 |
|
Mechanisms
of Action of Anti-gram-positive Agents Against MRSA - E. Breukink
(Netherlands) |
| 17:10-17:40 |
|
Treatment
Options for MRSA: Clinical Evidence - R. Corey (US) |
| 17:40-18:00 |
|
Panel
Discussion |
|
|
|
| OCTOBER
11, 2006 |
|
|
|
|
|
|
8:00-9:00 |
|
Silver
Sponsored Symposium |
|
|
C. difficile
Chair
persons:
D. Gerding and C. McDonald
|
| 8:00-8:30 |
|
C.
difficile in the community - C. McDonald |
| 8:30-9:00 |
|
Antibiotic
Resistance and Treatment Options -
D. Gerding (US) |
|
|
|
|
|
Clinical
Aspects
Chair
persons: D. Levine and E. Rubinstein
|
| 9:30-10:00 |
|
The
Future in Therapeutics - E.
Rubenstein (CA) |
| 10:00-10:20 |
|
S.
epidermidis Foreign Body Infections - F. Waldvogel (CH) |
| 10:20-10:40 |
|
Methicillin-resistance S. aureus Endocarditis -D.
Levine (US) |
| 10:40-11:00 |
|
Nursing
Home Bacteremia - S. aureus - J. Mylotte (US) |
| 11:00-11:20 |
|
Gram
Positive Infection as a Factor/Marker of Increased Mortality - Y. Carmeli
(IL) |
|
|
|
|
|
|
PK/PD of
New Anti-gram-postive agents
Chair Persons:
P. Tulkens and J. Schentag
|
| 11:20-11:50 |
|
Quinolones,
Macrolides, Beta-lactam, and Glycopeptides Against S. aureus - P. Tulkens (BE)
|
| 11:50-12:10 |
|
Glycopeptides/Lipopeptides
Against MRSA - M. Rybak (US) |
| 12:10-12:30 |
|
Antibiotic
Combinations for Everything - J. Schentag (US) |
|
|
|
| 13:30-16:00 |
|
Silver
Sponsored Symposium |
|
|
Non
Antibiotic Treatment Options
Chair
Persons: G.Garber and A. Fattom
|
| 13:30-14:00 |
|
Recombinant
Activated Protein C Against
Severe Gram-positive Infections-Useful? - G. Garber
(CA) |
| 14:00-14:30 |
|
Adjunct
Treatment for S. aureus Bacteremia - J. Patti (US) |
| 14:30-15:00 |
|
Immunotherapy
for Invasive S. aureus Infections - A. Fattom (US) |
| 15:00-15:30 |
|
Panel
Discussions |
|
|
|
